MCID: ADR009
MIFTS: 40

Adrenal Cortex Disease

Categories: Endocrine diseases

Aliases & Classifications for Adrenal Cortex Disease

MalaCards integrated aliases for Adrenal Cortex Disease:

Name: Adrenal Cortex Disease 12 15
Adrenal Cortex Diseases 45 74

Classifications:



External Ids:

Disease Ontology 12 DOID:3952
MeSH 45 D000303
UMLS 74 C0001614

Summaries for Adrenal Cortex Disease

MalaCards based summary : Adrenal Cortex Disease, also known as adrenal cortex diseases, is related to primary pigmented nodular adrenocortical disease and acute adrenal insufficiency. An important gene associated with Adrenal Cortex Disease is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Aldosterone synthesis and secretion and Corticotropin-releasing hormone signaling pathway. The drugs Mecasermin and Doxorubicin have been mentioned in the context of this disorder. Affiliated tissues include cortex, adrenal cortex and pituitary, and related phenotypes are Increased cell death HMECs cells and behavior/neurological

Wikipedia : 77 Situated along the perimeter of the adrenal gland, the adrenal cortex mediates the stress response... more...

Related Diseases for Adrenal Cortex Disease

Diseases related to Adrenal Cortex Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
# Related Disease Score Top Affiliating Genes
1 primary pigmented nodular adrenocortical disease 32.0 PDE11A POMC PRKAR1A
2 acute adrenal insufficiency 10.4 POMC REN
3 allergic encephalomyelitis 10.4 CRH POMC
4 gangliocytoma 10.4 CRH POMC
5 ovarian serous adenofibroma 10.4 NR3C1 POMC
6 inappropriate adh syndrome 10.4 POMC REN
7 bronchus adenoma 10.4 POMC SST
8 bronchial adenomas/carcinoids childhood 10.4 POMC SST
9 acidophil adenoma 10.4 POMC SST
10 allergic urticaria 10.4 CRH NR3C1
11 aldosterone-producing adenoma 10.4 CYP11B2 KCNJ5
12 hypoaldosteronism 10.4 REN POMC CYP11B2
13 familial glucocorticoid deficiency 10.3 REN POMC NR0B1
14 acth deficiency, isolated 10.3 CRH POMC
15 arthrogryposis, distal, type 3 10.3 NR3C2 REN
16 adrenal cortical adenoma 10.3 CYP11B1 POMC PRKAR1A
17 mental depression 10.3 CRH NR3C1 POMC
18 ectopic cushing syndrome 10.3 CRH POMC SST
19 chronic fatigue syndrome 10.3 CRH NR3C1 POMC
20 hormone producing pituitary cancer 10.3 PRKAR1A SST
21 scleredema adultorum 10.3 INS POMC
22 familial hyperaldosteronism 10.3 KCNJ5 CYP11B2 CYP11B1
23 pseudohypoaldosteronism, type i, autosomal dominant 10.3 NR3C2 REN
24 adenohypophysitis 10.3 POMC PRL
25 familial hypertension 10.2 CYP11B2 NR3C2 REN
26 pseudohyperkalemia, familial, 2, due to red cell leak 10.2 CYP11B2 NR3C2 REN
27 mood disorder 10.2 CRH NR3C1 POMC
28 steroid inherited metabolic disorder 10.2 CYP11B1 CYP11B2 POMC REN
29 male reproductive organ benign neoplasm 10.2 POMC PRKAR1A
30 hypothalamic disease 10.2 POMC CRH PRL
31 hypothyroidism, congenital, nongoitrous, 4 10.2 CRH POMC PRL
32 burns 10.2 CRH INS
33 sella turcica neoplasm 10.2 POMC PRL
34 tuberculum sellae meningioma 10.2 POMC PRL
35 duodenal somatostatinoma 10.2 INS SST
36 amenorrhea 10.2 CRH POMC PRL
37 postgastrectomy syndrome 10.2 INS SST
38 hypoadrenalism 10.2 CRH POMC
39 urinary system disease 10.1 INS POMC REN
40 pituitary infarct 10.1 SST PRL POMC
41 chiasmal syndrome 10.1 SST PRL POMC
42 melancholia 10.1 CRH PRL
43 prolactin producing pituitary tumor 10.1 PRL SST
44 pancreatic endocrine carcinoma 10.1 SST POMC INS
45 adrenal carcinoma 10.1 CRH CYP11B1 CYP11B2 POMC REN
46 tsh producing pituitary tumor 10.1 SST PRL POMC
47 endogenous depression 10.1 CRH INS NR3C1
48 pheochromocytoma 10.1 CRH POMC REN SST
49 functioning pituitary adenoma 10.1 SST PRL POMC
50 hypokalemia 10.1 REN POMC NR3C2 NR3C1

Graphical network of the top 20 diseases related to Adrenal Cortex Disease:



Diseases related to Adrenal Cortex Disease

Symptoms & Phenotypes for Adrenal Cortex Disease

GenomeRNAi Phenotypes related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death HMECs cells GR00103-A-0 9.02 INS NR0B1 NR3C1 NR3C2 USP8

MGI Mouse Phenotypes related to Adrenal Cortex Disease:

47 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.34 AIRE CRH CYP11B1 HSD11B1 INS NR3C1
2 homeostasis/metabolism MP:0005376 10.34 AIRE ARMC5 CRH CYP11B1 CYP11B2 HSD11B1
3 growth/size/body region MP:0005378 10.32 AIRE ARMC5 CRH CYP11B1 CYP11B2 HSD11B1
4 endocrine/exocrine gland MP:0005379 10.27 AIRE ARMC5 CRH CYP11B1 CYP11B2 HSD11B1
5 cardiovascular system MP:0005385 10.25 CYP11B1 CYP11B2 HSD11B1 INS KCNJ5 NR3C1
6 hematopoietic system MP:0005397 10.16 AIRE CRH CYP11B2 HSD11B1 INS NR3C1
7 immune system MP:0005387 10.14 AIRE CRH CYP11B2 HSD11B1 INS NR3C1
8 adipose tissue MP:0005375 10.08 CRH CYP11B2 HSD11B1 INS NR3C1 POMC
9 liver/biliary system MP:0005370 10.07 AIRE CRH CYP11B2 HSD11B1 INS NR3C1
10 mortality/aging MP:0010768 10.06 AIRE ARMC5 CYP11B1 INS NR3C1 NR3C2
11 nervous system MP:0003631 9.93 AIRE CRH CYP11B2 HSD11B1 INS NR3C1
12 muscle MP:0005369 9.8 CYP11B1 HSD11B1 INS NR3C1 NR3C2 PRKAR1A
13 renal/urinary system MP:0005367 9.56 CRH CYP11B1 CYP11B2 INS NR3C1 NR3C2
14 reproductive system MP:0005389 9.23 AIRE CYP11B2 INS NR0B1 NR3C1 PRKAR1A

Drugs & Therapeutics for Adrenal Cortex Disease

Drugs for Adrenal Cortex Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 162)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Mecasermin Approved, Investigational Phase 3 68562-41-4
2
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
3
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
4
Lenograstim Approved, Investigational Phase 3 135968-09-1
5
Cisplatin Approved Phase 3,Phase 2,Phase 1 15663-27-1 2767 441203 84093
6
Mitotane Approved Phase 3,Phase 2 53-19-0 4211
7
Streptozocin Approved, Investigational Phase 3 18883-66-4 29327
8
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1 31703
9 Antineoplastic Agents, Hormonal Phase 3,Phase 2
10 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
11 Antimitotic Agents Phase 3,Phase 2,Phase 1
12 insulin Phase 3,Phase 2
13 Insulin, Globin Zinc Phase 3,Phase 2
14 Mitogens Phase 3,Phase 2
15 Etoposide phosphate Phase 3,Phase 2
16 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
17 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
18 Immunologic Factors Phase 3,Phase 2,Phase 1
19 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
20 Adjuvants, Immunologic Phase 3,Phase 2,Phase 1
21 Keratolytic Agents Phase 3
22 Podophyllotoxin Phase 3 518-28-5
23 Dermatologic Agents Phase 3
24
Paclitaxel Approved, Vet_approved Phase 2,Phase 1 33069-62-4 36314
25
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
26
Epinephrine Approved, Vet_approved Phase 2,Phase 1,Not Applicable 51-43-4 5816
27
Racepinephrine Approved Phase 2,Phase 1,Not Applicable 329-65-7 838
28
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 2,Phase 1 1177-87-3
29
Dexamethasone Approved, Investigational, Vet_approved Phase 2,Phase 1 50-02-2 5743
30
Hydrocortisone Approved, Vet_approved Phase 2,Phase 1,Not Applicable 50-23-7 5754
31
Hydrocortisone acetate Approved, Vet_approved Phase 2,Phase 1,Not Applicable 50-03-3
32
Axitinib Approved, Investigational Phase 2 319460-85-0 6450551
33
acetic acid Approved Phase 2 64-19-7 176
34
Etomidate Approved Phase 1, Phase 2 33125-97-2 667484 36339
35
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
36
Vincristine Approved, Investigational Phase 2 2068-78-2, 57-22-7 5978
37
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
38
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
39
Oxaliplatin Approved, Investigational Phase 2 61825-94-3 43805 6857599 5310940 9887054
40
Sodium Citrate Approved, Investigational Phase 2 68-04-2
41
Tamoxifen Approved Phase 2 10540-29-1 2733526
42
nivolumab Approved Phase 2,Phase 1 946414-94-4
43
Ipilimumab Approved Phase 2 477202-00-9
44
Pembrolizumab Approved Phase 2 1374853-91-4
45
Vitamin A Approved, Nutraceutical, Vet_approved Phase 2 68-26-8, 22737-96-8, 11103-57-4 9904001 445354
46
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
47
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
48
Lactitol Investigational Phase 2 585-88-6, 585-86-4 493591
49 Gossypol Investigational Phase 2 303-45-7
50
Suramin Investigational Phase 2,Phase 1 145-63-1 5361

Interventional clinical trials:

(show top 50) (show all 80)
# Name Status NCT ID Phase Drugs
1 A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma Completed NCT00924989 Phase 3 OSI-906
2 Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor Completed NCT00304070 Phase 3 doxorubicin hydrochloride;cisplatin;mitotane;etoposide
3 Trial in Locally Advanced and Metastatic Adrenocortical Carcinoma Treatment (FIRM-ACT) Completed NCT00094497 Phase 3 Etoposide;Doxorubicin;Cisplatin;Streptozotocin;Mitotane
4 Adjuvant Chemotherapy vs. Observation/Mitotane After Primary Surgical Resection of Localized Adrenocortical CarcInoma Recruiting NCT03723941 Phase 3 Cisplatin plus Etoposide
5 Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Participants With Stage I-III Adrenocortical Cancer With High Risk of Recurrence (ADIUVO-2) Recruiting NCT03583710 Phase 3 Cisplatin;Etoposide;Mitotane
6 Efficacy of Adjuvant Mitotane Treatment (ADIUVO) Recruiting NCT00777244 Phase 3 MITOTANE
7 Sorafenib Plus Paclitaxel in Adreno-Cortical-Cancer Patients Unknown status NCT00786110 Phase 2 Sorafenib;Paclitaxel
8 Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Completed NCT02468193 Phase 2 Osilodrostat
9 Medical Safety Follow-up Study for Patients Who Received More Than 28 Days of Total Exposure to BGG492 Completed NCT02150213 Phase 2 BGG492
10 Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-Pathway in Metastatic, Recurrent or Primary Unresectable Adrenocortical Cancer Completed NCT01255137 Phase 2 Axitinib
11 Surgery and Heated Chemotherapy for Adrenocortical Carcinoma Completed NCT01833832 Phase 2 Cisplatin;sodium thiosulfate
12 Clinical Trial of Dovitinib in First-line Metastatic or Locally Advanced Non-resectable Adrenocortical Carcinoma Completed NCT01514526 Phase 2 Dovitinib
13 A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) Patients Completed NCT01262235 Phase 1, Phase 2 TKM-080301
14 Gossypol Acetic Acid in Treating Patients With Recurrent, Metastatic, or Primary Adrenocortical Cancer That Cannot Be Removed By Surgery Completed NCT00848016 Phase 2 R-(-)-gossypol acetic acid
15 Cixutumumab in Treating Patients With Relapsed or Refractory Solid Tumors Completed NCT00831844 Phase 2
16 Evaluation of 123I-Iodometomidate for Adrenal Scintigraphy Completed NCT00454103 Phase 1, Phase 2 123I-Iodometomidate
17 Sunitinib in Refractory Adrenocortical Carcinoma Completed NCT00453895 Phase 2 Sunitinib
18 Surgery Plus Chemotherapy (Doxorubicin, Vincristine and Etoposide), Mitotane, and Tariquidar to Treat Adrenocortical Cancer Completed NCT00071058 Phase 2 XR9576 (Tariquidar)
19 Trial With Taxotere and Cisplatin in Non-operable Adrenocortical Carcinoma Completed NCT00324012 Phase 2 cisplatin, taxotere
20 Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC) Completed NCT00215202 Phase 2 Iressa (ZD1839)
21 Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Completed NCT00091182 Phase 2 oxaliplatin
22 Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
23 A Study of Combination Chemotherapy and Surgical Resection in the Treatment of Adrenocortical Carcinoma: Continuous Infusion Doxorubicin, Vincristine and Etoposide With Daily Mitotane Before and After Surgical Resection Completed NCT00001339 Phase 2 doxorubicin, vincristine, and etoposide with mitotane
24 Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma Recruiting NCT03370718 Phase 2 Cabozantinib
25 Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary Tumors Recruiting NCT03333616 Phase 2 Ipilimumab;Nivolumab
26 Cabazitaxel Activity in Patients With Advanced AdrenoCortical-Carcinoma Progressing After Previous Chemotherapy Lines Recruiting NCT03257891 Phase 2 Cabazitaxel
27 Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma Recruiting NCT03127774 Phase 2 Cisplatin;Sodium thiosulfate
28 Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors Recruiting NCT02867592 Phase 2 Cabozantinib;Cabozantinib S-malate
29 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
30 Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic Recruiting NCT02721732 Phase 2
31 Activity of Abiraterone Acetate in the Management of Cushing's Syndrome in Patients With Adrenocortical Carcinoma Active, not recruiting NCT03145285 Phase 2 Abiraterone Acetate
32 Single Agent Pembrolizumab in Subjects With Advanced Adrenocortical Carcinoma Active, not recruiting NCT02673333 Phase 2 Pembrolizumab
33 Cabozantinib in Advanced Adrenocortical Carcinoma Not yet recruiting NCT03612232 Phase 2 Cabozantinib-s-malate
34 Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer Terminated NCT02720484 Phase 2 Nivolumab
35 IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Terminated NCT00778817 Phase 2 mitotane
36 S9427, Suramin in Treating Patients With Stage III or Stage IV Adrenocortical Cancer Incurable by Surgery Terminated NCT00002921 Phase 2 suramin;therapeutic hydrocortisone
37 Antineoplaston Therapy in Treating Patients With Stage IV Adrenal Gland Cancer Terminated NCT00003453 Phase 2 Antineoplaston therapy (Atengenal + Astugenal)
38 Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma Withdrawn NCT00469469 Phase 2 Bevacizumab
39 Adrenal Responsiveness During the Perioperative Period in Children Undergoing Congenital Cardiac Surgery Completed NCT01839812 Phase 1 Cosyntropin
40 Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma Completed NCT01898715 Phase 1 ATR-101
41 Seneca Valley Virus-001 and Cyclophosphamide in Treating Young Patients With Relapsed or Refractory Neuroblastoma, Rhabdomyosarcoma, or Rare Tumors With Neuroendocrine Features Completed NCT01048892 Phase 1 cyclophosphamide
42 Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin for Children With Peritoneal Cancer Completed NCT00436657 Phase 1 CHPP of Cisplatin
43 Combination Chemotherapy With Suramin Plus Doxorubicin in Treating Patients With Advanced Solid Tumors Completed NCT00003038 Phase 1 doxorubicin hydrochloride;suramin
44 Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu Completed NCT00004074 Phase 1
45 A Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Recruiting NCT02637531 Phase 1 IPI-549;Nivolumab
46 Possible New Therapy for Advanced Cancer Terminated NCT01832974 Phase 1 IL-13-PE
47 Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Withdrawn NCT02831179 Phase 1 Capecitabine;Temozolomide;Veliparib
48 The Effects of Case Management in a Medicaid Managed Care Plan Unknown status NCT00385879 Not Applicable
49 Laparoscopic Adrenalectomy Versus Radiofrequency Ablation Unknown status NCT02030587 Not Applicable
50 Does Serum-DXM Increase Diagnostic Accuracy of the Overnight DXM Suppression Test in the Work-up of Cushing's Syndrome? Unknown status NCT01504555

Search NIH Clinical Center for Adrenal Cortex Disease

Cochrane evidence based reviews: adrenal cortex diseases

Genetic Tests for Adrenal Cortex Disease

Anatomical Context for Adrenal Cortex Disease

MalaCards organs/tissues related to Adrenal Cortex Disease:

42
Cortex, Adrenal Cortex, Pituitary, Adrenal Gland, Testes, Liver, Bone

Publications for Adrenal Cortex Disease

Articles related to Adrenal Cortex Disease:

# Title Authors Year
1
Hypertension and adrenal cortex disease. A review of 100 autopsied cases. ( 5491407 )
1970

Variations for Adrenal Cortex Disease

Expression for Adrenal Cortex Disease

Search GEO for disease gene expression data for Adrenal Cortex Disease.

Pathways for Adrenal Cortex Disease

GO Terms for Adrenal Cortex Disease

Cellular components related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 endosome lumen GO:0031904 8.62 INS PRL

Biological processes related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 glucose homeostasis GO:0042593 9.73 CYP11B1 INS POMC
2 response to drug GO:0042493 9.72 CRH REN SST
3 regulation of blood pressure GO:0008217 9.65 CYP11B1 POMC REN
4 steroid biosynthetic process GO:0006694 9.63 CYP11B1 CYP11B2 NR0B1
5 adrenal gland development GO:0030325 9.58 CRH NR0B1
6 cellular response to peptide hormone stimulus GO:0071375 9.57 CYP11B1 CYP11B2
7 hypothalamus development GO:0021854 9.54 CRH NR0B1
8 C21-steroid hormone biosynthetic process GO:0006700 9.52 CYP11B1 CYP11B2
9 cellular response to potassium ion GO:0035865 9.49 CYP11B1 CYP11B2
10 steroid metabolic process GO:0008202 9.46 CRH CYP11B1 CYP11B2 HSD11B1
11 hormone-mediated apoptotic signaling pathway GO:0008628 9.43 CRH SST
12 cellular response to dexamethasone stimulus GO:0071549 9.43 CRH NR3C1 USP8
13 cellular response to hormone stimulus GO:0032870 9.4 CYP11B1 CYP11B2
14 aldosterone biosynthetic process GO:0032342 9.37 CYP11B1 CYP11B2
15 cortisol biosynthetic process GO:0034651 9.32 CYP11B1 CYP11B2
16 parturition GO:0007567 9.21 CRH
17 response to immobilization stress GO:0035902 9.13 CRH NR0B1 REN
18 glucocorticoid biosynthetic process GO:0006704 8.92 CRH CYP11B1 CYP11B2 HSD11B1

Molecular functions related to Adrenal Cortex Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 steroid hormone receptor activity GO:0003707 9.5 NR0B1 NR3C1 NR3C2
2 steroid binding GO:0005496 9.43 HSD11B1 NR3C1 NR3C2
3 3',5'-cyclic-GMP phosphodiesterase activity GO:0047555 9.4 PDE11A PRKAR1A
4 insulin-like growth factor receptor binding GO:0005159 9.37 INS REN
5 corticosterone 18-monooxygenase activity GO:0047783 9.16 CYP11B1 CYP11B2
6 hormone activity GO:0005179 9.02 CRH INS POMC PRL SST
7 steroid 11-beta-monooxygenase activity GO:0004507 8.96 CYP11B1 CYP11B2

Sources for Adrenal Cortex Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....